X
    X
    X
    X

    Zydus Pharmaceuticals (USA) Inc.

    A Locke Lord team represented Zydus Pharmaceuticals (USA) Inc. at trial against Shire Development LLC in Shire’s effort to prevent Zydus from bringing to market a generic version of the drug LIALDA® (mesalamine). Judge Kent Jordan, a Third Circuit appellate judge sitting by designation in the United States District Court for the District of Delaware, ruled that Zydus’s proposed generic product would not infringe Shire’s patent. LIALDA® is the first and only FDA-approved once-daily oral formulation of mesalamine indicated for the induction and maintenance of remission of ulcerative colitis. LIALDA® is also the number one prescribed mesalamine product in the United States. Shire has reported annual global sales of approximately $700 million for this product (which is sold under the name MEZAVANT outside the United States). The Locke Lord team representing Zydus included: Michael J. Gaertner, Keith D. Parr, James T. Peterka, David B. Abramowitz, Andy J. Miller, Wasim K. Bleibel and Timothy F. Peterson (all Chicago).

    Posted October 5, 2016

    Explore Additional Topics

    Disclaimer

    Please understand that your communications with Locke Lord LLP through this website do not constitute or create an attorney-client relationship with Locke Lord LLP. Any information you send to Locke Lord LLP through this website is on a non-confidential and non-privileged basis. Therefore, do not send or include any information in your email that you consider to be confidential or privileged.